As the industry shifts from volume to value based models, it is becoming necessary for Pharmaceutical companies to demonstrate the value their brands deliver through outcomes and evidence based studies. One example of such study is economic burden of inadequate symptom control.
As the industry shifts from volume to value based models, it is becoming necessary for Pharmaceutical companies to demonstrate the value their brands deliver through outcomes and evidence based studies. One example of such study is the economic burden of disease.
BERKELEY HEIGHTS, NJ, April 21, 2016 /24-7PressRelease/
Targeted therapies have generated great interest amongst pharmaceutical manufacturers and several products are currently being commercialized. With the advent of advanced data sources provided by companies who perform these diagnostic tests, it becomes more critical pharmaceutical manufacturers to enhance their understanding of diagnosis, testing, and treatment behaviors while building capabilities around the targeted therapies with accurate forecasting. The diagnostic testing data provided by the laboratories helps in evaluating the overall genetic testing landscape ranging from academic to commercial laboratories and make commercial recommendations around forecasting and localized decision making.
With 971% growth, Axtria blazes a trail as one of New Jersey's fastest-growing companies
Axtria Inc received the Future 50 award, its 3rd NJ based award in the last 6 months, adding to the NJTC and NJBiz awards received earlier. New Jersey SmartCEO and Norris McLaughlin & Marcus, P.A. and Wilkin & Guttenplan P.C. honored the 2016 Future 50 Award winners at a rock 'n' roll-themed awards ceremony on February 18, 2016 at The Palace at Somerset Park. The program recognizes the region's 50 fastest-growing, mid-sized companies and 5 small Emerging Growth companies who have experienced outsized growth based on a combined three-year average of revenue and employee growth.
Axtria now offers its cloud data analytics expertise in combination with Reltio’s cloud MDM platform. This partnership allows customers to get a clean, single source of data - and turns data into a strategic competitive advantage. Reltio, works with all data types including transactions, interactions, third-party, public and social data, to produce a multi-domain, single source of truth for master data for the enterprise. With this partnership, customers can now combine master data management with their analytics efforts, and get accurate, deeper and predictive insight at the point of decision.
With Reltio’s expertise in the Life Sciences industry through solutions such as Key Account Management, Key Opinion Leader Management, Managed Markets and Payer Management, it provides a perfect data management platform for Axtria’s customers. This is yet another step in establishing Axtria’s leadership in providing insights across integrated sales, marketing and real world evidence data to Life Science industry leaders.
The Reltio platform will power two Axtria offerings: First, Axtria SalesIQ™ platform, which provides integrated end-to-end sales operations services which will cross-leverage Reltio’s ability to predict, collaborate and respond to opportunities in real‑time. Second, Axtria’s Business Intelligence platform integrates with Reltio to support the convergence of data from multiple sources, functional areas and processes.
With this partnership, Reltio customers will not only be able to get a clean and single-source-of-truth for master data, but will also be able to leverage Axtria’s expertise across to strategically transform their sales and marketing operations through competitive insights and predictive analytics.
We, at Axtria, are truly excited and look forward to leveraging this partnership to further drive RoI on our investments.
Reltio delivers reliable data, relevant insights and recommended actions so companies can be right faster. Reltio Cloud combines data-driven applications with modern data management for better planning, customer engagement and risk management. Reltio enables IT to streamline data management for a complete view across all sources and formats at scale, while sales, marketing and compliance teams use data-driven applications to predict, collaborate and respond to opportunities in real-time. Companies of all sizes, including leading Fortune 500 companies in healthcare and life sciences, distribution and retail rely on Reltio. For more information, visit www.reltio.com.
Axtria has been selected as a finalist of the Innovative Technology Company of the Year at the 19th NJTC Annual Awards. The Awards ceremony will be held on the evening of November 19, 2015 at the Renaissance Woodbridge Hotel in Iselin, NJ.
The award includes a video highlighting each finalist which will be seen by the evening’s guests. The award information will also be reflected in the Commemorative Awards Program which will be distributed to the 400+ Celebration guests.
In addition, TechNews, the region’s premier technology publication, will focus its entire October issue on the Awards Celebration winners/finalists.
We are proud to announce that Axtria is this year’s winner of Whitepaper Competition for Millennials on “Leveraging SMAC for HR” 2015, conducted by American Chamber of Commerce (AmCham) India – an association of American business organizations operating in India with over 500 member companies of US origin.
In the second PMSA Webinar Series 2015 session, which is a one-of-its-kind platform for discussion and collaboration on best practices in sales operations, Axtria’s David Wood (PhD) and Rajnish Kumar delivered another engaging session on ‘Sales Force Sizing & Portfolio Optimization’. The webinar discussed the various approaches to determining the best sales force size (SFS) and covered several key areas such as: